Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape.

Subbiah IM, Tsimberidou A, Subbiah V, Janku F, Roy-Chowdhuri S, Hong DS.

Oncoscience. 2017 Jun 23;4(5-6):47-56. doi: 10.18632/oncoscience.352. eCollection 2017 May.

2.
3.

New Challenges in Targeting Signaling Pathways in Acute Lymphoblastic Leukemia by NGS Approaches: An Update.

Montaño A, Forero-Castro M, Marchena-Mendoza D, Benito R, Hernández-Rivas JM.

Cancers (Basel). 2018 Apr 7;10(4). pii: E110. doi: 10.3390/cancers10040110. Review.

4.

Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types.

Schwaederle M, Elkin SK, Tomson BN, Carter JL, Kurzrock R.

Cell Cycle. 2015;14(14):2355-61. doi: 10.1080/15384101.2015.1053669. Epub 2015 Jun 1.

5.

Genomic landscape of salivary gland tumors.

Kato S, Elkin SK, Schwaederle M, Tomson BN, Helsten T, Carter JL, Kurzrock R.

Oncotarget. 2015 Sep 22;6(28):25631-45. doi: 10.18632/oncotarget.4554.

6.

Enabling a genetically informed approach to cancer medicine: a retrospective evaluation of the impact of comprehensive tumor profiling using a targeted next-generation sequencing panel.

Johnson DB, Dahlman KH, Knol J, Gilbert J, Puzanov I, Means-Powell J, Balko JM, Lovly CM, Murphy BA, Goff LW, Abramson VG, Crispens MA, Mayer IA, Berlin JD, Horn L, Keedy VL, Reddy NM, Arteaga CL, Sosman JA, Pao W.

Oncologist. 2014 Jun;19(6):616-22. doi: 10.1634/theoncologist.2014-0011. Epub 2014 May 5.

7.

A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.

Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, Wang B, Wu Y, Cronin MT, Palmer G, Symmans WF, Miller VA, Stephens P, Pusztai L.

Oncologist. 2014 May;19(5):453-8. doi: 10.1634/theoncologist.2013-0377. Epub 2014 Apr 7.

8.

Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary.

Kato S, Krishnamurthy N, Banks KC, De P, Williams K, Williams C, Leyland-Jones B, Lippman SM, Lanman RB, Kurzrock R.

Cancer Res. 2017 Aug 15;77(16):4238-4246. doi: 10.1158/0008-5472.CAN-17-0628. Epub 2017 Jun 22.

9.

Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors.

Wheler JJ, Atkins JT, Janku F, Moulder SL, Stephens PJ, Yelensky R, Valero V, Miller V, Kurzrock R, Meric-Bernstam F.

Oncoscience. 2016 Jun 30;3(5-6):164-72. doi: 10.18632/oncoscience.307. eCollection 2016.

10.

RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients.

Kato S, Subbiah V, Marchlik E, Elkin SK, Carter JL, Kurzrock R.

Clin Cancer Res. 2017 Apr 15;23(8):1988-1997. doi: 10.1158/1078-0432.CCR-16-1679. Epub 2016 Sep 28.

11.

Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas.

Lee JJ, Sholl LM, Lindeman NI, Granter SR, Laga AC, Shivdasani P, Chin G, Luke JJ, Ott PA, Hodi FS, Mihm MC Jr, Lin JY, Werchniak AE, Haynes HA, Bailey N, Liu R, Murphy GF, Lian CG.

Clin Epigenetics. 2015 Jun 9;7:59. doi: 10.1186/s13148-015-0091-3. eCollection 2015.

12.

Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity.

Beltran H, Yelensky R, Frampton GM, Park K, Downing SR, MacDonald TY, Jarosz M, Lipson D, Tagawa ST, Nanus DM, Stephens PJ, Mosquera JM, Cronin MT, Rubin MA.

Eur Urol. 2013 May;63(5):920-6. doi: 10.1016/j.eururo.2012.08.053. Epub 2012 Sep 5.

13.

Bias-Corrected Targeted Next-Generation Sequencing for Rapid, Multiplexed Detection of Actionable Alterations in Cell-Free DNA from Advanced Lung Cancer Patients.

Paweletz CP, Sacher AG, Raymond CK, Alden RS, O'Connell A, Mach SL, Kuang Y, Gandhi L, Kirschmeier P, English JM, Lim LP, Jänne PA, Oxnard GR.

Clin Cancer Res. 2016 Feb 15;22(4):915-22. doi: 10.1158/1078-0432.CCR-15-1627-T. Epub 2015 Oct 12.

14.

Defining the genomic landscape of head and neck cancers through next-generation sequencing.

Rizzo G, Black M, Mymryk JS, Barrett JW, Nichols AC.

Oral Dis. 2015 Jan;21(1):e11-24. doi: 10.1111/odi.12246. Epub 2014 Apr 30. Review.

PMID:
24725020
15.

Gene-expression profiling elucidates molecular signaling networks that can be therapeutically targeted in vestibular schwannoma.

Agnihotri S, Gugel I, Remke M, Bornemann A, Pantazis G, Mack SC, Shih D, Singh SK, Sabha N, Taylor MD, Tatagiba M, Zadeh G, Krischek B.

J Neurosurg. 2014 Dec;121(6):1434-45. doi: 10.3171/2014.6.JNS131433. Epub 2014 Sep 23.

PMID:
25245477
16.

Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.

Ross JS, Badve S, Wang K, Sheehan CE, Boguniewicz AB, Otto GA, Yelensky R, Lipson D, Ali S, Morosini D, Chliemlecki J, Elvin JA, Miller VA, Stephens PJ.

Arch Pathol Lab Med. 2015 May;139(5):642-9. doi: 10.5858/arpa.2014-0200-OA.

17.

Multipoint targeting of the PI3K/mTOR pathway in mesothelioma.

Zhou S, Liu L, Li H, Eilers G, Kuang Y, Shi S, Yan Z, Li X, Corson JM, Meng F, Zhou H, Sheng Q, Fletcher JA, Ou WB.

Br J Cancer. 2014 May 13;110(10):2479-88. doi: 10.1038/bjc.2014.220. Epub 2014 Apr 24.

18.

Simultaneous perturbation of the MAPK and the PI3K/mTOR pathways does not lead to increased radiosensitization.

Kuger S, Flentje M, Djuzenova CS.

Radiat Oncol. 2015 Oct 24;10:214. doi: 10.1186/s13014-015-0514-5.

19.

Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing.

Abdul SN, Ab Mutalib NS, Sean KS, Syafruddin SE, Ishak M, Sagap I, Mazlan L, Rose IM, Abu N, Mokhtar NM, Jamal R.

Front Pharmacol. 2017 Jul 18;8:465. doi: 10.3389/fphar.2017.00465. eCollection 2017.

20.

Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.

Polivka J Jr, Janku F.

Pharmacol Ther. 2014 May;142(2):164-75. doi: 10.1016/j.pharmthera.2013.12.004. Epub 2013 Dec 9. Review.

PMID:
24333502

Supplemental Content

Support Center